European Medicines Agency recommends granting a marketing authorisation for trastuzumab emtansine

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product trastuzumab emtansine (Kadcyla), 100 mg and 160 mg, powder for concentrate for solution for infusion intended for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Read more here.